echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Eli Lilly's donanemab treats Alzheimer's disease with mixed results

    Eli Lilly's donanemab treats Alzheimer's disease with mixed results

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Eli Lilly shared more details of the highly anticipated Phase II TRAILBLAZER-ALZ trial, which tested the beta-amyloid-targeted antibody donanemab in early symptomatic Alzheimer’s disease Role in the patient.


    Eli Lilly said that donanemab "continuously slows down" cognitive and functional decline, which is statistically significant compared to placebo.


    However, in the NEJM report, the authors of the study described the secondary results as "mixed good and bad", and most of the results did not have "substantial differences" compared to placebo.


    Participants were randomly assigned to receive intravenous donanemab or placebo every four weeks for a maximum of 72 weeks.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.